Oxford Biotech OMass Therapeutics Secures €275 Million Series C to Advance Small-Molecule Pipeline
Oxford spin‑out OMass Therapeutics raised €275 million in a Series C round co‑led by Bain Capital Life Sciences, Forbion and Novo Holdings to push its novel small‑molecule therapies, including OMS1620 for congenital adrenal hyperplasia, into the clinic.